Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 2;14:5681–5686. doi: 10.2147/JIR.S326382

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Saito et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Effect of linagliptin on IL-6 production in LPS (100 pg /mL, 1 μg/mL) induced and anti-TLR4 antibodies treated cells in absence of FBS. Human U937 monocytes were treated with linagliptin and anti-TLR4 antibodies after induction with LPS (100 pg /mL, 1 μg/mL). IL-6 levels in the supernatants were determined by enzyme-linked immunosorbent assay (ELISA) after 24 h of treatment. *P < 0.05 vs A-TLR4 10 μg/mL alone.

Abbreviations: IL, interleukin; LPS, lipopolysaccharide; A-TLR, anti-Toll-like receptor; Lina, linagliptin.